| CatalogCode: | | NB100-105 |
| ProductName: | | HIF-1 alpha Antibody |
| Product Description: | | Mouse Monoclonal anti-HIF-1 alpha (H1alpha67) |
| Clone: | | H1alpha67 |
| Clonality: | | Monoclonal |
| Immunogen: | | Fusion protein containing amino acids 432-528 of human HIF-1alpha. |
| Specificity: | | This antibody is specific for HIF-1 alpha. |
| CrossReactivity: | | NB 100-105 recognizes human, monkey, sheep, mouse, rat, rabbit, pig, bovine and ferret HIF-1alpha. |
| Packaging: | | 0.25 ml protein G purified Mouse ascites. |
| Uses: | | By Western blot, this antibody recognizes bands at 120 kDa representing HIF-1 alpha in induced tissues and cells. Multiple bands may be seen at 100-120 kDa representing post-translational modification of HIF-1alpha. This antibody has been used to immunoprecipitate human HIF-1 alpha. For ChIP, see Kong, et al. |
| Localization: | | HIF-1 is a nuclear protein. |
| Control: | | Nuclear Extracts recommended NB800-PC26 Cos-7 Nuclear extracts NB810-55229 PC12 Nuclear Extracts |
| Background: | | Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. HIF-1 is a nuclear protein involved in mammalian oxygen homeostasis. This occurs as a posttranslational modification by prolyl hydroxylation. HIF-1 is a heterodimer composed of HIF-1 alpha and HIF-1 beta subunits. Both subunits are constantly translated. However, under normoxic conditions, human HIF-1 alpha is hydroxylated at Pro402 or Pro564 by a set of HIF prolyl hydroxylases, is polyubiquinated, and eventually degraded in proteosomes. Under hypoxic conditions, the lack of hydroxylation prevents HIF degradation and increases transcriptional activity. Therefore, the concentration of HIF-1 alpha increases in the cell. In contrast, HIF-1 beta remains stable under either condition. HIF hydroxylases provide insight into hypoxic cell responses, which may be used to help isolate therapeutic targets. |
| Storage: | | Store at 4C. Do not freeze. |
| Purity: | | protein G purified |
| Isotype: | | IgG2b |
| Host_Name: | | Mouse |
| Buffer: | | PBS |
| ListPrice: | | 285 |
| NovusRef: | | 1. Alberghini, A., et al. (2005) J. Biol. Chem. 280(34): 30120-30128. [Western blot, Human] 2. Aminova, L.R., et al. (2005) J. Biol. Chem. 280(5): 3996-4003. [Western blot, Mouse] 3. Asikainen, T. M., et al. (2006) FASEB J. 20: 1698-1700. 4. Bateman, R. M., et al. (2007) Am J. Physiol. Heart Circ. Physiol. 293: H448-H456. 5. Bernhardt, W. M., et al (2006) J. Am Soc. Nephrol. 17: 1970-1978. 6. Bernhardt, W. M., et al. (2007) Am. J. Pathol. 170: 830-842. 7. Birner, P., et al. (2000) Can. Res. 60: 4693-4696. [Immunohistochemistry-paraffin, Human] 8. Birner, P., et al. (2001) Cancer. 92(1): 165-71, 2001. [Immunohistochemistry-paraffin, Human] 9. Birner, P., et al. (2001) Clin. Can. Res. 7(6): 1661-1668. [Immunohistochemistry-paraffin, Human] 10. Biswas, S., et al. (2007) Am J Physiol. Heart Circ. Physiol. 292: H758-766. 11. Bracken, C. P., et al. (2006) J. Biol. Chem. 281: 22575-22585. 12. Brooks, C., et al. (2007) Am J Physiol. Renal Physiol. 292: F243-252. 13. Carroll, P. A., et al. (2006) J. Virol. 80: 10802-10812. 14. Chade, A. R., et al. (2006) FASEB J. 20: 1706-1708.. 15. Chavez, J. C., et al. (2006) J. Neurosci. 26: 9471-9481. 16. Chen, H., et al. (2006) Can. Res. 66: 9009-9016. 17. Chin, BY, et al. (2007) PNAS. 0609611104. 18. Creighton-Gutteridge, M., et al. (2007) Can. Res. 13: 1010-1018. 19. Duyndam, M.C.A., et al. (2001) J. Biol. Chem. 276(51):48066-48076. [Western blot, Human] 20. Fath, D. M., et al. (2006) J. Biol. Chem. 281: 13612-13619. 21. Franco, M., et al. (2006) Can. Res. 66(7): 3639-3648. 22. Galabova-Kovacs, G., et al. (2006) PNAS. 103: 1325-1330. 23. Gothie, E., et a l. (2000) J. Biol. Chem. 275(10):6922-6927. [Western blot, Human] 24. Grimmer, C., et al. (2006) J. Pathol. 169: 491-502. 25. Groenman, F., et al. (2007) J. Histochem. and Cytochem. 55(4): 355-363. 26. Higami, Y., et al. (2006) J. Nutrition. 136: 343-352. 27. Hsu, T., et al, V. (2006) J. Biol. Chem. 281: 12069-12080. 28. Hu, C-J., et al. (2006) Mol. Cell Biol. 26: 3514-3526. 29. Hui, A. S., et al. (2006) J. Biol. Chem. 20: 466-475. 30. Hwang, I. I. L., et al. (2006) J. Virol. 80: 10712-10723. 31. Ivan, M., et al. (2002) PNAS. 99: 13459-13464. 32. Ivan, M., et al. (2001) Science. 292(5516): 464-8. [Immunoprecipitation] 33. Jayle, C., et al. (2007) Am. J. Physiol. Renal Physiol. 292: F1082-1093. 34. Jeong, C.-H., et al. (2007) J. Biol. Chem. 282(18): 13672-13679. 35. Kamura, T., et al. (2000) PNAS. 97: 10430-10435. 36. Kang, S.-H., et al. (2006) Healthscience J. 66: 11991-11997. 37. Khan, Z., et al. (2006) J. Pathol. 169: 1251-1269. 38. Khurana, A., et al. (2006) J. Biol. Chem. 281: 35316-35326. 39. Knies-Bamforth, U.E., et al. (2004) Can. Res. 64:6563-6570. [Western blot, Mouse] 40. Kojima, I., et al. (2007) J. Am. Soc. Nephrol. 18: 1218-1226. 41. Kong, D., et al. (2005) Can. Res. 65: 9047-9055. 42. Lang, S. A., et al. (2007) Molec. Can. Therap. 6: 1123-1132. 43. LaRusch, G. A., et al. (2007) Can. Res. 67: 450-454. 44. Lee, K. S., et al. (2006) Molec. Pharmac. 35: 190-197. 45. Lee, K. S., et al. (2006) Molec. Pharmac. 69: 1829-1839. 46. Li, L., et al. (2006) Can. Res. 12: 4747-4754. 47. Liao, H., et al. (2007) FASEB J. 21: 935-949. 48. Lin, A. D.-Y., et al. (2006) J. Endocrinol. 190: 241-246. 49. Liu, W., et al. (2006) Blood. 107: 698-707. 50. Lukashev, D., et al. (2006) J. Immunol. 177: 4962-4965. 51. Luo, Y., et al. (2006) Molec. Pharmac. 69: 1953-1962. 52. Makino, H., et al. (2006) Diabetes J., 55: 2747-2756. 53. McLaren, A. T., et al. (2007) Am J Physiol. Regul. Integr Comp Physiol. 292: R403-414. 54. McLaren, A., et al. (2006) Canadian J. Anesthesiol. 53: 26367. 55. McMahon, S., et al. (2006) J. Biol. Chem. 281: 24171-24181. 56. Nemetski, S. M., and Gardner, L. B. (2007) J. Biol. Chem. 282: 240-248. 57. Nickols, N. G., et al. (2007) Nuc. Acid Res. 35: 363-370. 58. Nishimura, R., et al. (2006) J. Endocrinol. 147: 4273-4280. 59. Oda, T., et al. (2006) Am. J. Physiol. Cell Physiol. 291: C104-113. 60. Pacary, E., et al. (2006) J. Cell Sci. 119: 2667-2678. 61. Palladino, M., et al. (2002) Biol. Reprod. 67: 995-1002. [Immunocytochemistry, Western blot, Rat] 62. Park, J., et al. (2003) Clin. Can. Res. 9:433-440. [Western blot, Human] 63. Pore, N., et al. (2006) Can. Res. 66: 9252-9259. 64. Pore, N., et al. (2006) Can. Res. 66: 3197-3204. 65. Powell, J.D. et al. (2004) Biol. Reprod. 70: 121-1130. [Immunocytochemistry, Rat] 66. Quintero, M., et al. (2006) Can. Res. 66: 770-774. 67. Rodriguez-Porcel, M., et al. (2006) Am. J. Physiol. Heart Circ. Physiol. 290: H978-984. 68. Ronkainen, V.-P., et al. (2007) FASEB. fj.06-7294com. 69. Rosenberger, C., et al. (2007) J. Am. Soc. Nephrol. 18: 343-351. 70. Schindl, M., et al. (2002) Clin. Can. Res. 8: 1831-1837. [Immunohistochemistry-paraffin, Human] 71. Shen, F., et al. (2006) Stroke. 37: 2601-2606. 72. Shimojo, N., et al. (2007) Am. J. Physiol. Heart Circ. Physiol. 293: H474-481. 73. Sumiyoshi, Y., et al. (2006) Can. Res. 12(17): 5112-5117. 74. Sutter, C.H., et al. (2000) PNAS. 97: 4748-4753. 75. Tanaka, T., et al. (2006) J. of Gerontol. Series A. 61: 795-805. 76. Trentin, D., et al. (2006) PNAS. 103: 2506-2511. 77. Veschini, L., et al. (2007) Blood. 109: 2565-2570. 78. Villanueva, S., et al. (2006) Am. J. Physiol. Regul. Comp. Physiol. 291: R1677-1687. 79. Villanueva, S., et al. Am. J. Physiol. Regul. Comp. Physiol. 2006; 290: R861-870. 80. Wang, J., et al. J. Biol. Chem. 2006; 281: 213-220. 81. Wang, R., et al. FASEB J. 2006; 20: 1275-1277. 82. Winner, M., et al. Can. Res. 2007; 67: 186-193. 83. Zagzag, D., et al. Can. Res. 2005; 65: 6178-6188. 84. Zampino, M., et al. Am. J. Physiol. Heart Circ. Physiol. 2006; 291: H957-964. 85. Zhang, X., et al. J. Biol. Chem. 2007; 282(15): 10873-10880. 86. Zhong, H., et al. Can. Res. 1999; 59: 5830-5835. [Immunohistochemistry-paraffin, Mouse, Human] 87. Zhang, H., et al. Can. Cell. 2007; 11: 407-420. 88. Liu, Y. et al. J. Biol. Chem. 2007; 10.1074/jbc.M705015200. 89. Baek, J.H. et al. J. Biol. Chem. 2007; 282(46): 33358-33366. 90. Baek, J.H. et al J. Biol. Chem. 2007; 282(32): 23572-23580. 100. Lam, W., C.-H. Leung, et al. The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine. 2007; 72: 536-544. 101. Ide, T., Y. Kitajima, et al. The Hypoxic Environment in Tumor-Stromal Cells Accelerates Pancreatic Cancer Progression via the Activation of Paracrine Hepatocyte Growth Factor/c-Met Signaling. Annals of Surgical Oncology. 2007; 14: 2600-2607. 102. Villanueva,S., et al. Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. Am J Physiol Regulatory Integrative Comp Physiol, Jan 2008. 103. Engebretsen, B., et al. Acute Hypobaric Hypoxia (5486 m) Induces greater Pulmonary HIF-1 Activation in Hilltop Compared to Madison Rats. High Altitude Medicine and Biology. 2007; 8(4): 312-321. 104. Cheng G, Shao Z, Chaudhari B, Agrawal DK. Involvement of chloride channels in TGF-beta1-induced apoptosis of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. November 1, 2007; 293(5):L1339-47. 105. Black SM, DeVol JM, Wedgwood S. Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. Am J Physiol Cell Physiol. January 1, 2008; 294(1):C345-54. 106. McLaren, A., et al. Increased expression of HIF-1alpha, nNOS, and VEGF in the cerebral cortex of anemic rats. Am. J. Physiol. Regul. Comp. Physiol. 2007 292:R403-R414. 107. Zhang, H., M. Bosch-Marce, et al. Mitochondrial autophagy is a HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008: M800102200 p. 108. Higgins, D. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 2007; 117(12): 3810-3820. doi:10.1172/JCI30487. 109. Han S, Wang G, Qi X, Lee HM, Englander EW, Greeley JGH. A Possible Role For Hypoxia-Induced Apelin Expression in Enteric Cell Proliferation. Am J Physiol Regulatory Integrative Comp Physiol. March 26, 2008:00083.2008. 110. Iwazu Y, Muto S, Fujisawa G, et al. Spironolactone Suppresses Peritubular Capillary Loss and Prevents Deoxycorticosterone Acetate/Salt-Induced Tubulointerstitial Fibrosis. Hypertension. March 1, 2008;51(3):749-54. 111. Murphy BJ, Kimura T, Sato BG, Shi Y, Andrews GK. Metallothionein Induction by Hypoxia Involves Cooperative Interactions between Metal-Responsive Transcription Factor-1 and Hypoxia-Inducible Transcription Factor-1{alpha}. Mol Cancer Res. March 1, 2008;6(3):483-90. 112. Weidemann A, Bernhardt WM, Klanke B, et al. HIF Activation Protects From Acute Kidney Injury. J Am Soc Nephrol. March 1, 2008;19(3):486-94. (immunohistochemistry) 113. Kaukinen A, Kuusniemi A-M, Lautenschlager I, Jalanko H. Glomerular endothelium in kidneys with congenital nephrotic syndrome of the Finnish type (NPHS1). Nephrol Dial Transplant. April 1, 2008;23(4):1224-32. 114. Nagao K, Taniyama Y, Kietzmann T, Doi T, Komuro I, Morishita R. HIF-1{alpha} Signaling Upstream of NKX2.5 Is Required for Cardiac Development in Xenopus. J Biol Chem. April 25, 2008;283(17):11841-9. 115. Rosenberger C, Goldfarb M, Shina A, et al. Evidence for sustained renal hypoxia and transient hypoxia adaptation in experimental rhabdomyolysis-induced acute kidney injury. Nephrol Dial Transplant. April 1, 2008;23(4):1135-43. 116. Frew IJ, Minola A, Georgiev S, et al. COMBINED VHLH AND PTEN MUTATION CAUSES GENITAL TRACT CYSTADENOMA AND SQUAMOUS METAPLASIA. Mol Cell Biol. May 12, 2008:MCB.02132-07. 117. Korgaonkar SN, Feng X, Ross MD, et al. HIV-1 Upregulates VEGF in Podocytes. J Am Soc Nephrol. May 1, 2008;19(5):877-83. 118. Li N, Chen L, Yi F, Xia M, Li P-L. Salt-Sensitive Hypertension Induced by Decoy of Transcription Factor Hypoxia-Inducible Factor-1{alpha} in the Renal Medulla. Circ Res. May 9, 2008;102(9):1101-8. 119. Lin S-K, Shun C-T, Kok S-H, Wang C-C, Hsiao T-Y, Liu C-M. Hypoxia-Stimulated Vascular Endothelial Growth Factor Production in Human Nasal Polyp Fibroblasts: Effect of Epigallocatechin-3-Gallate on Hypoxia-Inducible Factor-1{alpha} Synthesis. Arch Otolaryngol Head Neck Surg. May 1, 2008;134(5):522-7. 120. Ryu J, Lee C-W, Hong K-H, et al. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia. Cardiovasc Res. May 1, 2008;78(2):333-40. 121. Yamashita T, Ohneda O, Sakiyama A, Iwata F, Ohneda K, Fujii-Kuriyama Y. The microenvironment for erythropoiesis is regulated by HIF-2{alpha} through VCAM-1 in endothelial cells. Blood. May 1, 2008:blood-2007-11-122648. |
| AppSummary: | | ChIP, IHC, IF, IP, WB, IHC-Fr |
| SpeciesSummary: | | Bv, Hu, Mu, Po, Mk, Rt, Ft, Sh |
| ALTnames: | | anti-Hypoxia-inducible factor 1 alpha antibody, anti-HIF1 alpha antibody, anti-ARNT interacting protein antibody, anti-Hif1a antibody, anti-ARNT interacting protein antibody, anti-HIF-1alpha antibody, anti-Hypoxia inducible factor 1 alpha antibody, anti-Hypoxia inducible factor 1 alpha subunit basic helix antibody |
| ProteinTarget: | | HIF-1 alpha (Hypoxia-inducible factor 1 alpha) |
| PackageSize: | | 0.25 ml |
| NotesMain: | | Lot V is 1.5mg/ml Lot U is 2.0 mg/ml You may use COS-7 treated and untreated nuclear extracts for your positive and negative controls for hypoxic upregulation, NB800-PC26 * The mobility of HIF-1 alpha induced by desferrioxamine or cobalt chloride treatment differs from the mobility of the hypoxia-induced protein. The reason is not known. |
| more information: | | company product webpage |
|